Andere talen ANGN BIOM

Aandelen

ANGN

US03476J1079

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,85 ^USD	-3,80%		-4,32%	-11,50%

2023	Angion Biomedica Corp. kondigt aan dat Assaf Segal ontslag heeft genomen uit de Raad van Bestuur	CI
2023	Angion Biomedia gaat 10-voor-1 omgekeerde splitsing doorvoeren	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer	08/04
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting	05/04
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates	29/03
Elicio Therapeutics Announces $6.0 Million Private Placement Financing	18/03
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting	06/03
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	25/01
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference	16/01
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	09/01
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	04/12
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	09/11
ANGN BIOM : Lymph Node Targeted AMP-peptide Vaccines Generate Functional T cell Immunity Against Mutant p53 and BRAF (SITC – Scientific Poster)	03/11
ANGN BIOM : ELI-002 Immunotherapy Induces Broad Polyfunctional T cell Responses in Subjects with High Relapse Risk KRAS Mutated Pancreatic Ductal Adenocarcinoma and Colorectal Cancer (SITC – Scientific Poster)	03/11
ANGN BIOM : Management Change - Form 8-K	12-10-23
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting	11-10-23
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer	27-09-23
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines	07-09-23
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	06-09-23
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer	05-09-23
Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	30-08-23
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics	28-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ANGN BIOM

Aandelen

ANGN

US03476J1079

Andere talen

Filters